The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
Open accessAbstract
Seliciclib (CYC202; R-roscovitine) is the first selective, orally bioavailable inhibitor of cyclin-dependent kinases 1, 2, 7 and 9 to enter clinical trial. Preclinical studies showed antitumour activity in a broad range of human tumour xenografts. A phase I trial was performed with a 7-day b.i.d. p.o. schedule. Twenty-one patients (median age 62 years, range: 39-73 years) were treated with doses of 100, 200 and 800 b.i.d. Dose-limiting toxicities were seen at 800 mg b.i.d.; grade 3 fatigue, grade 3 skin rash, grade 3 hyponatraemia and grade 4 hypokalaemia. Other toxicities included reversible raised creatinine (grade 2), reversible grade 3 abnormal liver function and grade 2 emesis. An 800 mg portion was investigated further in 12 patients, three of whom had MAG3 renograms. One patient with a rapid increase in creatinine on day 3 had a reversible fall in renal perfusion, with full recovery by day 14, and no changes suggestive of renal tubular damage. Further dose escalation was precluded by hypokalaemia. Seliciclib reached peak plasma concentrations between 1 and 4 h and elimination half-life was 2-5 h. Inhibition of retinoblastoma protein phosphorylation was not demonstrated in peripheral blood mononuclear cells. No objective tumour responses were noted, but disease stabilisation was recorded in eight patients; this lasted for a total of six courses (18 weeks) in a patient with ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors
Gray, N. S., Wodicka, L., Thunnissen, A.-M. W. H., Norman, T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., LeClerc, S., Meijer, L., et al. (1998) · Science · doi:10.1126/science.281.5376.533 · Cited by 808
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice
Ortega, S., Prieto, I., Odajima, J., Martín, A., Dubus, P., Sotillo, R., Barbero, J. L., Malumbres, M., & Barbacid, M. (2003) · Nature Genetics · doi:10.1038/ng1232 · Cited by 796
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793
De Azevedo, W. F., Leclerc, S., Meijer, L., Havlicek, L., Strnad, M., & Kim, S. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.0518a.x · Cited by 729
Proliferation of cancer cells despite CDK2 inhibition
Tetsu, O., & McCormick, F. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00053-9 · Cited by 466
Senderowicz, A. M., Headlee, D., Stinson, S. F., Lush, R. M., Kalil, N., Villalba, L., Hill, K., Steinberg, S. M., Figg, W. D., Tompkins, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2986 · Cited by 403
McClue, S. J., Blake, D., Clarke, R., Cowan, A., Cummings, L., Fischer, P. M., MacKenzie, M., Melville, J., Stewart, K., Wang, S., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10738 · Cited by 364
Roscovitine and Other Purines as Kinase Inhibitors. From Starfish Oocytes to Clinical Trials
Meijer, L., & Raymond, E. (2003) · ChemInform · doi:10.1002/chin.200336265 · Cited by 362
Roscovitine Targets, Protein Kinases and Pyridoxal Kinase
Bach, S., Knockaert, M., Reinhardt, J., Lozach, O., Schmitt, S., Baratte, B., Koken, M., Coburn, S. P., Tang, L., Jiang, T., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500806200 · Cited by 356
Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms
Sausville, E. A., Arbuck, S. G., Messmann, R., Headlee, D., Bauer, K. S., Lush, R. M., Murgo, A., Figg, W. D., Lahusen, T., Jaken, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2319 · Cited by 291
MacCallum, D. E., Melville, J., Frame, S., Watt, K., Anderson, S., Gianella-Borradori, A., Lane, D. P., & Green, S. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0233 · Cited by 288
Self-citationWhittaker, S. R., Walton, M. I., Garrett, M. D., & Workman, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0110 · Cited by 195
Self-citationRaje, N., Kumar, S., Hideshima, T., Roccaro, A., Ishitsuka, K., Yasui, H., Shiraishi, N., Chauhan, D., Munshi, N. C., Green, S. R., et al. (2005) · Blood · doi:10.1182/blood-2005-01-0320 · Cited by 187
Complexities in the development of cyclin-dependent kinase inhibitor drugs
Sausville, E. A. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02308-0 · Cited by 160
Alvi, A. J., Austen, B., Weston, V., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2713 · Cited by 133
Activation of p53 by roscovitine-mediated suppression of MDM2 expression
Lu, W., Chen, L., Peng, Y., & Chen, J. (2001) · Oncogene · doi:10.1038/sj.onc.1204412 · Cited by 131
Raynaud, F. I., Whittaker, S. R., Fischer, P. M., McClue, S. J., Walton, M. I., Barrie, S. E., Garrett, M. D., Rogers, P., Clarke, S. J., Kèlland, L. R., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2264 · Cited by 131
Self-citationPhase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol
Thomas, J. P., Tutsch, K. D., Cleary, J. F., Bailey, H. H., Arzoomanian, R. Z., Alberti, D. B., Simon, K., Feierabend, C., Binger, K., Marnocha, R., et al. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0527-2 · Cited by 123
The Effect of the Cyclin-Dependent Kinase Inhibitor Olomoucine on Cell Cycle Kinetics
Schütte, B., Nieland, L. J. W., van Engeland, M., Henfling, M. E. R., Meijer, L., & Ramaekers, F. C. S. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3700 · Cited by 108
Clinical anticancer drug development: targeting the cyclin-dependent kinases
Benson, C., Kaye, S. B., Workman, P., Garrett, M. D., Walton, M., & Bono, J. S. D. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602229 · Cited by 103
Self-citationCrystal Structure of Pyridoxal Kinase in Complex with Roscovitine and Derivatives
Tang, L., Li, M., Cao, P., Wang, F., Chang, W., Bach, S., Reinhardt, J., Ferandin, Y., Galons, H., Wan, Y., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500805200 · Cited by 81
Tan, A. R., Yang, X., Berman, A. W., Zhai, S., Sparreboom, A., Parr, A. L., Chow, C., Brahim, J. S., Steinberg, S. M., Figg, W. D., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0025 · Cited by 72
Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse.
Nutley, B. P., Raynaud, F. I., Wilson, S. C., Fischer, P. M., Hayes, A., Goddard, P. M., McClue, S. J., Jarman, M., Lane, D. P., & Workman, P. (2005) · PubMed · Cited by 71
Self-citationPharmacokinetic model of R-roscovitine and its metabolite in healthy male subjects
de la Motte, S., & Gianella-Borradori, A. (2004) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp42232 · Cited by 49
Self-citationRaynaud, F. I., Fischer, P. M., Nutley, B. P., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.353.3.3 · Cited by 44
Self-citationAntitumor effect of valorphin in vitro and in vivo: Combined action with cytostatic drugs
Blishchenko, E. Y., Sazonova, O. V., Kalinina, O. A., Moiseeva, E. V., Vass, A. A., Karelin, A. A., & Ivanov, V. T. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.1.1474 · Cited by 36
Cited by
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Cell cycle kinases as therapeutic targets for cancer
Lapenna, S., & Giordano, A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2907 · Cited by 905
Natural Products as Leads to Potential Drugs: An Old Process or the New Hope for Drug Discovery?
Newman, D. J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm0704090 · Cited by 716
CDC25 phosphatases in cancer cells: key players? Good targets?
Boutros, R., Lobjois, V., & Ducommun, B. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2169 · Cited by 714
Metadata
- Authors
- Benson, C., White, J., Bono, J. D., O'Donnell, A., Raynaud, F., Cruickshank, C., McGrath, H., Walton, M., Workman, P., Kaye, S., Cassidy, J., Gianella-Borradori, A., Judson, I., & Twelves, C.
- Venue
- British Journal of Cancer
- Published
- 2006-12-19
- Volume
- 96
- Issue
- 1
- Pages
- 29-37
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2083433702
- Cited by
- 261
- References
- 28
- FWCI
- 15.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.